Table 3.
Ongoing or recently completed clinical trials involving molecules that target apoptosis
| Molecule name | Sponsor | Target | Condition | Clinical stage |
|---|---|---|---|---|
| ABT-263 (in combination with erlotinib or irinotecan) |
Abbott | Bcl-2 family of proteins | Solid tumours | Phase I |
| ABT-263 (in combination with docetaxel) |
Abbott | Bcl-2 family of proteins | Solid tumours | Phase I |
| ABT-263 (in combination with paclitaxel) |
Abbott | Bcl-2 family of proteins | Chronic lymphocytic leukaemia | Phase I |
| ABT-263 | Genentech | Bcl-2 family of proteins | Chronic lymphocytic leukaemia | Phase II |
| AT-101 (Gossypol) |
Roswell Park Cancer Institute | Bcl-2 family of proteins | Lymphocytic leukaemia, chronic B-cell leukaemia |
Phase I Phase II |
| AT-406 | Ascenta Therapeutics | IAPs | Solid tumours, lymphoma |
Phase I |
| AT-406 | Ascenta Therapeutics | IAPs | Acute myelogenous leukaemia | Phase I |
| ENZ-3042 | Therapeutic Advances in Childhood Leukaemia Consortium | IAPs | Acute, childhood and T cell lymphoblastic leukaemia | Phase I |
| GX15-070MS (Obotoclax) |
Children's Oncology Group | Bcl-2 family of proteins | Leukaemia, lymphoma unspecified childhood solid tumour |
Phase I |
| GX15-070MS (Obotoclax) |
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute | Bcl-2 family of proteins | Lymphoma | Phase I Phase II |
| HGS-1029 | Human Genome Sciences | IAPs | Advanced solid tumours | Phase I |
| HGS-1029 | Human Genome Sciences | IAPs | Advanced solid tumours | Phase I |
| LCL-161 | Novartis Pharmaceuticals | IAPs | Solid tumours | Phase I |
| RO5458640 | Hoffmann-La Roche | TNF-like weak inducer of apoptosis (TWEAK) ligand | Advanced solid tumours | Phase I |